Juvaris BioTherapeutics ink deal

The animal division of Bayer Healthcare and the Juvaris BioTherapeutics company have agreed a licensing deal that will aim to boost the scientific development efforts of both businesses.

Juarvis is currently developing vaccine technology that it believes could have potential use not only for animals but also for human beings and the agreement relates to all of its activities around the world.

Financial details of the licensing agreement have not been disclosed but Bayer Healthcare is to have full access to the technologies and therapies developed by Juarvis going forward.

Bosses of both companies have stressed that the important aspect of the agreement is that it will establish a long-term collaborative structure between operations working in similar fields.

Lykele van der Broek, president of Bayer’s animal health division, said: “The beauty about this cooperation is that it is not just about one single product.

“It serves as a platform technology that helps us develop a wide range of applications in several species for numerous indications in preventing infectious diseases.”

Last month, the chairman of Bayer Healthcare’s management board Werner Wenning hailed 2007 as the most successful year in the company’s history.